Abstract
The placental transport of carnitine is significant because the fetus cannot supply itself with adequate amounts of this nutrient. Carnitine deficiencies in infants can lead to symptoms ranging from muscle weakness to sudden infant death. Objectives of this study include the characterization of novel organic cation transporter 2 (OCTN2) function in the BeWo cell line and the inhibition of placental carnitine uptake by amphetamine derivatives. BeWo cells were seeded in 12- or 24-well tissue culture plates and incubated at 37°C until monolayers were confluent. Uptake studies with radiolabeled l-carnitine and inhibitors in Hanks' balanced salt solution were carried out in the plates at 37°C for 30 min. Uptake of l-carnitine in BeWo cells was Na+-dependent and saturable (Km = 9.8 ± 2.4 μM, Vmax = 800 ± 70 pmol/mg of protein/30 min) with a nonsaturable constant of 2.8 ± 0.3 μl/mg of protein/30 min. Among the amphetamine analogs studied, IC50 values ranged from 2.3 to 9.2 mM, and the inhibition of carnitine uptake was stronger for compounds having a methyl-substituted nitrogen atom. Lineweaver-Burk plots show that inhibition by tetraethylammonium and valproate was competitive; inhibition by ephedrine was not completely competitive. The observed kinetics, Western blot, and inhibition profiles indicate that high-affinity carnitine uptake in the BeWo cell line is mediated by OCTN2. Inhibition of carnitine transport by amphetamines potentially poses serious consequences for fetal development.
Footnotes
-
Financial support for this work has been supplied by the Madison and Lila Self Graduate Fellowship, the University of Kansas Department of Pharmaceutical Chemistry, and Grant HD039878 from the National Institute of Child Health and Human Development. A portion of this work was presented at the AAPS 2003 Annual Meeting, 2003 October 26–30; Salt Lake City, UT. AAPS PharmSci Vol. 5, Abstract T2153 (2003).
-
doi:10.1124/jpet.104.072363.
-
ABBREVIATIONS: OCT, organic cation transporter; OCTN2, novel organic cation transporter 2; PBS, phosphate-buffered saline; HBSS, Hanks' balanced salt solution; TEA, tetraethylammonium; MPP+, 1-methyl-4-phenylpyridinium; MES, 2-(N-morpholino)ethanesulfonic acid.
- Received June 7, 2004.
- Accepted August 17, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|